Rafferty Asset Management
SPRO icon

Rafferty Asset Management’s Spero Therapeutics SPRO Stock Holding History

Rafferty Asset Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-34,958
Closed -$560K – 1316
2021
Q4 		$560K Buy
34,958
+16,169
+86% +$257K ﹤0.01% 1038
2021
Q3 		$346K Sell
18,789
-5,109
-21% -$82K ﹤0.01% 1110
2021
Q2 		$334K Sell
23,898
-45,065
-65% -$630K ﹤0.01% 1154
2021
Q1 		$1.01M Buy
+68,963
New +$1.21M 0.01% 768

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Rafferty Asset Management's SPRO Position: Q1 2022 in Review

Rafferty Asset Management sold out of Spero Therapeutics (SPRO) in Q1 2022, closing a stake of 34,958 shares — an estimated $560K sold.

Rafferty Asset Management first reported a position in SPRO in Q1 2021 and held it in 4 quarters. The position peaked at $1.01M in Q1 2021. 100 funds tracked by Wall St. Rank hold SPRO as of Q1 2022.

  • Rafferty Asset Management reported no remaining Spero Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 34,958 Spero Therapeutics shares in Q1 2022, an estimated $560K.
  • Rafferty Asset Management first reported a position in Spero Therapeutics in Q1 2021 and held it in 4 quarters.
  • Rafferty Asset Management's Spero Therapeutics position peaked at $1.01M in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2022.

Based on Rafferty Asset Management's 13F filing for Q1 2022, filed 13 May 2022.